Tatyana Li

Dr. Tatyana Li

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Open access
DADauren Ayaganov
Dauren Ayaganov
AKAidyn Kuanyshbek
Aidyn Kuanyshbek
IVIvan Vakhrushev
Ivan Vakhrushev
TLTatyana Li
Tatyana Li
Cardiac surgery with cardiopulmonary bypass (CPB) is associated with hypofibrinogenemia and severe bleeding requiring transfusion. Guidelines recommend cryoprecipitate or fibrinogen concentrate (FC) for the treatment of acquired hypofibrinogenemia. This study compared cryoprecipitate and FC for the correction of acquired hypofibrinogenemia and the associated costs. A single-center, prospective, randomized study evaluating patients with hypofibrinogenemia after cardiac surgery. The primary endpoint was direct treatment cost. Secondary endpoints included the change in fibrinogen level after FC and/or cryoprecipitate dosing. A single-center study in Astana, Kazakhstan. Participants who underwent CPB from 2021 to 2022 and developed clinically significant bleeding and hypofibrinogenemia. Patients were randomized to receive cryoprecipitate or FC. Eighty-eight adult patients with acquired hypofibrinogenemia (<2.0 g/L) after CPB were randomized to receive cryoprecipitate (N = 40) or FC (N = 48), with similar demographics between groups. Overall, mean ± SD 9.33 ± 0.94 units (range, 8-10) cryoprecipitate or 1.40 ± 0.49 g (1-2) FC was administered to the 2 groups. From before administration to 24 hours after, mean plasma fibrinogen increased by a mean ± SD of 125 ± 65 and 96 ± 65 mg/dL in the cryoprecipitate and FC groups, respectively. At 48 hours after administration, there was no significant difference in fibrinogen levels between groups. The mean direct cost of treatment with FC was significantly lower than with cryoprecipitate (p < 0.0001): $1,505.06 ± $152.40 and $631.75 ± $223.67 per patient for cryoprecipitate and FC, respectively. Analysis of plasma fibrinogen concentration showed that cryoprecipitate and FC had comparable effectiveness. However, FC is advantageous over cryoprecipitate due to its ease of handling, lower cost, and high purity.

14 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TLTatyana Li
Tatyana Li
Azhar ZhailauovaAzhar Zhailauova
Azhar Zhailauova
AKAidyn Kuanyshbek
Aidyn Kuanyshbek
IWIwan Wachruschew
Iwan Wachruschew
STShaimurat Tulegenov
Shaimurat Tulegenov
TKTimur Kapyshev
Timur Kapyshev
Heparin resistance (HR) in patients on extracorporeal membrane oxygenation (ECMO) exacerbates bleeding and thrombogenesis. Thus far, there is no universal definition of what this condition entails and no unified strategy for assessing heparin’s efficacy in ECMO patients. The most frequent discrepancy when it comes to defining HR is the difference in the reported doses: units per day (U/d) or per kilogram per hour (U/kg/h). Another disagreement arises with regard to the various methods of measuring unfractionated heparin (UFH) efficacy. Due to numerous processes that begin with ECMO initiation, including protein layer formation on the surface of circuits, the recruitment of immune cells, the activation of complement and contact activation systems, and platelets, assessing pure antithrombin consumption is complicated. Moreover, there is an alternative anticoagulation procedure performed by a serine protease inhibitor named heparin cofactor II, which could also contribute to heparin consumption. Considering simultaneously launched processes of inflammation and thrombogenesis in response to contact with artificial surfaces on ECMO, we listed the possible mechanisms contributing to additional antithrombin consumption. The effect of the flow on the platelets’ activation and von Willebrand factor (vWF) assembly was also described. We reviewed the scientific literature from PubMed and Embase to identify possible definitions of heparin resistance during ECMO treatment among pediatric and adult cohorts. We identified 13 records describing different approaches to assessing HR and described our vision of delineating HR on ECMO.

18 August 2024 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
NJNilufar Jabayeva
Nilufar Jabayeva
TLTatyana Li
Tatyana Li
AKAidyn Kuanyshbek
Aidyn Kuanyshbek
AZAzhar Zhailauova
Azhar Zhailauova
AAAinamkoz Amanzholova
Ainamkoz Amanzholova
NMNurila Maltabarova
Nurila Maltabarova
Acute kidney injury (AKI) is a condition characterized by a sudden decline in kidney function, leading to accumulation of waste products and fluids in the body. It is a common and serious complication in patients with cardiovascular diseases, and it is associated with increased morbidity and mortality. Aim In this study, we explore the relationship between cardiac issues and the development of AKI, as well as strategies for its prevention and management. The primary aim of this study is to examine the incidence and risk factors for the AKI in patients admitted to the cardiac intensive care unit/CICU), as well as the impact of AKI on patient outcomes. Methods We conducted prospective observational single center study. 292 consecutive patients admitted to ICU after open heart surgery by sternotomy were included. Patients were monitored in ICU for frequency of AKI, perioperative risk factors, cardiac surgery-associated acute kidney injury (CSA-AKI) and their impact on patients’ outcome. Results After admission to the intensive care unit, 33 patients (11.3%) developed CSA-AKI in the postoperative period. According to the analysis, male gender (p=0.03), decreased GFR (p=0.02) as well as high EuroSCORE II (p=0.013), hemoglobin level before surgery (p = 0.002) and the presence of diabetes and chronic kidney disease (p=0.03) were independent predictors of AKI after open-heart surgery. In patients who developed AKI, the duration of artificial lung ventilation was increased (21.3 vs 9.9 hours p = 0.001) and the duration of stay in the intensive care unit (4.3 vs. 1.9 days, P = 0.02). Conclusion: Patients often have AKI after heart surgery. EuroSCORE II, gender, diabetes, time of cardiopulmonary bypass and chronic kidney disease are independent predictors of AKI development. The appearance of AKI is due to an unfavorable outcome of events. The appearance of acute kidney injury is associated with adverse consequences. Key words: Acute kidney injury, cardiac surgery, predictors of AKI, postoperative period. Conflict of interests: The authors declare no conflict of interest.

17 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ZAZere Aidynbek
Zere Aidynbek
EKErken Kakenov
Erken Kakenov
OMOlga Mironova
Olga Mironova
KYKarlygash Ydyrysheva
Karlygash Ydyrysheva
TLTatyana Li
Tatyana Li
VSVitaliy Sazonov
Vitaliy Sazonov
Background/Objectives: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency that occurs in pediatric patients undergoing chemotherapy. Severe complications, including acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and cardiogenic shock, may require extracorporeal membrane oxygenation (ECMO) support. Methods: This paper is a nonsystematic review of cases that synthesizes available case reports to evaluate the efficacy and outcomes of ECMO in pediatric TLS. Results: A systematic search identified five cases in which ECMO was used with a mean duration of 14 days. Survival rates were favorable and ECMO played a critical role in bridging these patients through multi-organ failure. Conclusions: While ECMO is a viable rescue therapy for severe TLS, associated complications, such as infections, bleeding, and neurological impairment, warrant careful patient selection and management. Future studies should explore standardized guidelines for the use of ECMO in pediatric oncology patients.

9 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TLTatyana Li
Tatyana Li
Azhar ZhailauovaAzhar Zhailauova
Azhar Zhailauova
AKAidyn Kuanyshbek
Aidyn Kuanyshbek
IWIwan Wachruschew
Iwan Wachruschew
STShaimurat Tulegenov
Shaimurat Tulegenov
TKTimur Kapyshev
Timur Kapyshev
Heparin resistance (HR) on ECMO exacerbates bleeding and thrombogenesis. So far, there is no universal definition of HR on ECMO and no unified strategy for the assessment of heparin efficacy in ECMO patients. The most frequent discrepancy in defining HR is the difference in reported doses: units per day (U/d) or per kilogram per hour (U/kg/h). Another disagreement occurs ow-ing to different ways of measuring UFH efficacy, contributing to further disagreement in a com-mon definition of HR. Due to numerous processes that start with ECMO initiation, including protein layer formation on the surface of the circuits, recruitment of immune cells, activation of complement and contact activation systems, and platelets, the assessment of pure antithrombin consumption is complicated. Moreover, there is an alternative anticoagulation performed by a serine protease inhibitor named Heparin Cofactor II, the contribution of which could also be measured on heparin consumption. Considering simultaneously launched processes of inflam-mation and thrombogenesis in response to contact with artificial surfaces on ECMO, we listed possible mechanisms contributing to additional antithrombin consumption. The effect of the flow on the platelets activation and vWF assembly was also described. We examined the literature from Pubmed and Embase to find possible definitions of heparin resistance on ECMO among pediatric and adult cohorts. We extracted 13 records with different HR assessment approaches and sug-gested our vision of delineating HR on ECMO.

19 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TLTatyana Li
Tatyana Li
Azhar ZhailauovaAzhar Zhailauova
Azhar Zhailauova
IWIwan Wachruschew
Iwan Wachruschew
AKAidyn Kuanyshbek
Aidyn Kuanyshbek
STShaimurat Tulegenov
Shaimurat Tulegenov
Theodoros AslanidisTheodoros Aslanidis
Theodoros Aslanidis
Background: Discontinuing mechanical ventilation during cardiopulmonary bypass (CPB) is common but may adversely affect postoperative pulmonary function. This study aimed to evaluate the impact of stopping ventilation during CPB on postoperative gas exchange, radiographic findings, intensive care unit (ICU) length of stay (LOS), mortality, reintubation, re-exploration, and bleeding. Methods: A prospective observational study was performed involving adult patients scheduled for elective cardiac surgery requiring CPB. Participants were divided into ventilated and non-ventilated groups according to intraoperative strategy. Postoperative arterial carbon dioxide levels (PaCO2), arterial partial pressure of oxygen (PaO2), the PaO2/FiO2 ratio (P/F ratio), arterial oxygen saturation (SaO2), and the ratio of PaCO2 to minute ventilation (PaCO2/MV) were measured before the induction of anesthesia (within 5 min after transportation into the operating room), postoperatively within 5–10 min after transportation to the ICU, and in a 24 h postoperative period. Chest X-ray data, mechanical ventilation time, LOS in ICU, re-exploration, reintubation, and bleeding parameters were documented. Analyses were also conducted with the estimation of the age effect and BMI. Results: Individuals in the non-ventilated group exhibited lower postoperative P/F ratios and elevated postoperative PaCO2 and PaCO2/MV ratios. The difference in gas exchange leveled off within 24 h. There was no difference in the incidence of atelectasis (postoperatively in a 24 h period), mechanical ventilation time, LOS in ICU, or mortality. However, the incidence of bleeding was higher in the non-ventilated group (χ2 = 5.78, p = 0.016). Interestingly, postoperative PaCO2 and PaCO2/MV peaked in the 50-year age group. Conclusions: Continued mechanical ventilation during CPB correlates with better postoperative gas exchange, better CO2 clearance, and fewer bleeding events. The results suggest that maintaining low tidal volume ventilation during CPB may provide benefits, especially for patients aged 50 years.